We conducted a large cohort study using HuProtTM microarrays and reported that five autoantibodies of IgG and seven IgA were comprehensively involved in differentiating IBS patients from healthy controls with a sensitivity and specificity of 40%–46.7% and 79.4%–86.3%, respectively; however, no specific autoantibodies could serve as serum biomarkers for IBS (Fan et al., 2022). This evidence concerns the gene CD79A and irritable bowel syndrome.